Macrogenics (MGNX) Liabilities and Shareholders Equity (2012 - 2026)

Macrogenics (MGNX) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $217.9 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $217.9 million, down 2.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $990.9 million (up 4.1% YoY), and the FY2025 annual result was $256.8 million, down 1.84% from the prior year.
• Liabilities and Shareholders Equity declined to $217.9 million in Q1 2026 per MGNX's latest filing, from $256.8 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $343.5 million in Q1 2023 and troughed at $195.3 million in Q3 2022.
• A 5-year average of $261.4 million and a median of $261.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity sank 50.19% in 2022, then surged 74.03% in 2023.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $280.5 million in 2022, then advanced by 6.4% to $298.4 million in 2023, then fell by 12.32% to $261.7 million in 2024, then decreased by 1.84% to $256.8 million in 2025, then retreated by 15.17% to $217.9 million in 2026.
• Business Quant data shows MGNX's Liabilities and Shareholders Equity at $217.9 million in Q1 2026, $256.8 million in Q4 2025, and $270.8 million in Q3 2025.